



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

1

Complete if Known

Application Number	10/607,479
Filing Date	June 26, 2003
First Named Inventor	Lawrence S. Young et al.
Art Unit	1633
Examiner Name	Scott D. Priebe
Attorney Docket Number	HARR0032-101

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SDP	BY	BESNARD-GUERIN, C. ET AL., "HIV-1 Vpu Sequesters β -Transducin Repeat-containing Protein (β TrCP) in the Cytoplasm and Provokes the Accumulation of β -Catenin and Other SCF ^{βTrCP} Substrates, <i>J. Biological Chemistry</i> , 279(1):788-795, January 2, 2004	
	BZ	CHEON, S.S. ET AL., " β -Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds," <i>PNAS</i> , 99(10):6973-6978, May 14, 2002	
	CA	CHILOSI, M. ET AL., "Aberrant Wnt/ β -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis, <i>American Journal of Pathology</i> , 162(5):1495-1502, May, 2003	
	CB	MAK, B.C. ET AL., "The Tuberin-Hamartin Complex Negatively Regulates β -Catenin Signaling Activity, <i>J. Biological Chemistry</i> , 278(8):5947-5951, 2003	
	CC	MOON, R.T. ET AL., "WNT and β -Catenin Signalling: Diseases and Therapies," <i>Nature Reviews, Genetics</i> , 5:689-699, September, 2004	

Examiner Signature	Scott D. Priebe	Date Considered	2/16/06
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**A COPY OF THIS REFERENCE WILL NOT BE FORWARDED TO THE U.S. PATENT AND TRADEMARK OFFICE SINCE IT IS BELIEVED TO BE TOO VOLUMINOUS AND EASILY OBTAINABLE BY THE EXAMINER.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.